Research programme: anticancer monoclonal antibodies - AbbVie/Caprion Proteomics

Drug Profile

Research programme: anticancer monoclonal antibodies - AbbVie/Caprion Proteomics

Alternative Names: Lung cancer therapeutics research programme - AbbVie/Caprion

Latest Information Update: 23 Jan 2013

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Caprion Pharmaceuticals
  • Developer AbbVie; Caprion Proteomics
  • Class Monoclonal antibodies
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Preclinical Non-small cell lung cancer

Most Recent Events

  • 23 Jan 2013 Abbott separates its pharmaceuticals business to new company called AbbVie
  • 23 Sep 2011 This research programme appears to still be active
  • 26 Aug 2009 This programme is in active development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top